<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36676175</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">226</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life13010226</ELocationID><Abstract><AbstractText>Chronic olfactory dysfunction after SARS-CoV-2 infection occurs in approximately 10% of patients with COVID-19-induced anosmia, and it is a growing public health concern. A regimen of olfactory training and anti-neuroinflammatory therapy with co-ultramicronized palmitoylethanolamide with luteolin (um-PEA-LUT) has shown promising results in clinical trials; however, approximately 15% of treated patients do not achieve full recovery of a normal olfactory threshold, and almost 5% have no recovery. Disease-modifying therapies (DMTs), which are used to treat autoimmune neuroinflammation in multiple sclerosis (MS), have not been studied for treating persistent inflammation in refractory post-COVID-19 smell disorder. This study evaluated COVID-19-related smell loss and MS-related smell loss, comparing the responses to different therapies. Forty patients with MS and 45 reporting post-COVID-19 olfactory disorders were included in the study. All patients underwent nasal endoscopy and were evaluated by using validated Sniffin' Sticks testing. The patients with long COVID were treated for three months with um-PEA-LUT plus olfactory training. The patients with MS were treated with DMTs. Olfactory functions before and after treatment were analyzed in both groups. At the experimental endpoint, 13 patients in the COVID-19 group treated with um-PEA-LUT had residual olfactory impairment versus 10 patients in the MS group treated with DMTs. The severity of the persistent olfactory loss was lower in the MS group, and the patients with MS treated with IFN-beta and glatiramer acetate had the preservation of olfactory function. These data provide a rationale for considering prospective trials investigating the efficacy of DMTs for post-COVID-19 olfactory disorders that are refractory to um-PEA-LUT with olfactory training. This study is the first to consider the role of DMT in treating refractory post-viral olfactory loss in patients with long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Stadio</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5510-3814</Identifier><AffiliationInfo><Affiliation>GF Ingrassia Department, Otolaryngology, University of Catania, 95124 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernitsas</LastName><ForeName>Evanthia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9382-1008</Identifier><AffiliationInfo><Affiliation>Multiple Sclerosis Center, Neurology Department, Wayne State University, Detroit, MI 48202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Mantia</LastName><ForeName>Ignazio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>GF Ingrassia Department, Otolaryngology, University of Catania, 95124 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-4926-0957</Identifier><AffiliationInfo><Affiliation>Otolaryngology Department, Michigan University, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralli</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8776-0421</Identifier><AffiliationInfo><Affiliation>Department of Sense Organs, La Sapienza University, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaira</LastName><ForeName>Luigi Angelo</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-7789-145X</Identifier><AffiliationInfo><Affiliation>Oro-Maxillo-Facial Department, University of Sassari, 07100 Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colizza</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0639-806X</Identifier><AffiliationInfo><Affiliation>Department of Sense Organs, La Sapienza University, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavaliere</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Sense Organs, La Sapienza University, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laudani</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University La Sapienza, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frohman</LastName><ForeName>Teresa C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Distinguished Senior Fellows (Sabbatical), Laboratory of Neuroimmunology of Professor Lawrence Steinman, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vincentiis</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Sense Organs, La Sapienza University, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frohman</LastName><ForeName>Elliot M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Distinguished Senior Fellows (Sabbatical), Laboratory of Neuroimmunology of Professor Lawrence Steinman, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altieri</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3110-5932</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University La Sapienza, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">TDM</Keyword><Keyword MajorTopicYN="N">anosmia</Keyword><Keyword MajorTopicYN="N">disease-modifying therapy</Keyword><Keyword MajorTopicYN="N">hyposmia</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">long-haul COVID</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">olfaction</Keyword><Keyword MajorTopicYN="N">olfactory</Keyword><Keyword MajorTopicYN="N">olfactory training</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">smell</Keyword><Keyword MajorTopicYN="N">smell disorders</Keyword><Keyword MajorTopicYN="N">threshold detection identification</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36676175</ArticleId><ArticleId IdType="pmc">PMC9863729</ArticleId><ArticleId IdType="doi">10.3390/life13010226</ArticleId><ArticleId IdType="pii">life13010226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>H&#xfc;ttenbrink K.B., Hummel T., Berg D., Gasser T., H&#xe4;hner A. Olfactory dysfunction: Common in later life and early warning of neurodegenerative disease. Dtsch. Arztebl. Int. 2013;110:1&#x2013;7.e1. doi: 10.3238/arztebl.2013.0001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2013.0001</ArticleId><ArticleId IdType="pmc">PMC3561743</ArticleId><ArticleId IdType="pubmed">23450985</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A., Klein R.S. Neuroinflammation and COVID-19. Curr. Opin. Neurobiol. 2022;76:102608. doi: 10.1016/j.conb.2022.102608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2022.102608</ArticleId><ArticleId IdType="pmc">PMC9239981</ArticleId><ArticleId IdType="pubmed">35863101</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoy K., Mariotte D., Defer G., Petit G., Toutirais O., Le Mauff B. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front. Immunol. 2020;11:549842. doi: 10.3389/fimmu.2020.549842.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.549842</ArticleId><ArticleId IdType="pmc">PMC7541830</ArticleId><ArticleId IdType="pubmed">33072089</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis--the plaque and its pathogenesis. N. Engl. J. Med. 2006;354:942&#x2013;955. doi: 10.1056/NEJMra052130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra052130</ArticleId><ArticleId IdType="pubmed">16510748</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinescu C.S., Raps E.C., Cohen J.A., West S.E., Doty R.L. Olfactory disturbances as the initial or most prominent symptom of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1994;57:1011&#x2013;1012. doi: 10.1136/jnnp.57.8.1011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.57.8.1011</ArticleId><ArticleId IdType="pmc">PMC1073101</ArticleId><ArticleId IdType="pubmed">8057099</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty R.L., Li C., Mannon L.J., Yousem D.M. Olfactory dysfunction in multiple sclerosis. N. Engl. J. Med. 1997;336:1918&#x2013;1919. doi: 10.1056/NEJM199706263362617. Erratum in N. Engl. J. Med. 1997, 337, 507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199706263362617</ArticleId><ArticleId IdType="pubmed">9198762</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty R.L., Li C., Mannon L.J., Yousem D.M. Olfactory dysfunction in multiple sclerosis: Relation to longitudinal changes in plaque numbers in central olfactory structures. Neurology. 1999;53:880&#x2013;882. doi: 10.1212/WNL.53.4.880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.4.880</ArticleId><ArticleId IdType="pubmed">10489062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes C.H., Shephard B.C., Kobal G. Assessment of olfaction in multiple sclerosis: Evidence of dysfunction by olfactory evoked response and identification tests. J. Neurol. Neurosurg. Psychiatry. 1997;63:145&#x2013;151. doi: 10.1136/jnnp.63.2.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.63.2.145</ArticleId><ArticleId IdType="pmc">PMC2169670</ArticleId><ArticleId IdType="pubmed">9285449</ArticleId></ArticleIdList></Reference><Reference><Citation>Good K.P., Tourbier I.A., Moberg P., Cuzzocreo J.L., Geckle R.J., Yousem D.M., Pham D.L., Doty R.L. Unilateral olfactory sensitivity in multiple sclerosis. Physiol. Behav. 2017;168:24&#x2013;30. doi: 10.1016/j.physbeh.2016.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physbeh.2016.10.017</ArticleId><ArticleId IdType="pmc">PMC5135634</ArticleId><ArticleId IdType="pubmed">27780720</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivadinov R., Zorzon M., Monti Bragadin L., Pagliaro G., Cazzato G. Olfactory loss in multiple sclerosis. J. Neurol. Sci. 1999;168:127&#x2013;130. doi: 10.1016/S0022-510X(99)00189-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00189-6</ArticleId><ArticleId IdType="pubmed">10526195</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorzon M., Ukmar M., Bragadin L.M., Zanier F., Antonello R.M., Cazzato G., Zivadinov R. Olfactory dysfunction and extent of white matter abnormalities in multiple sclerosis: A clinical and MR study. Mult. Scler. 2000;6:386&#x2013;390. doi: 10.1177/135245850000600605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245850000600605</ArticleId><ArticleId IdType="pubmed">11212134</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutterotti A., Vedovello M., Reindl M., Ehling R., DiPauli F., Kuenz B., Gneiss C., Deisenhammer F., Berger T. Olfactory threshold is impaired in early, active multiple sclerosis. Mult. Scler. 2011;17:964&#x2013;969. doi: 10.1177/1352458511399798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458511399798</ArticleId><ArticleId IdType="pubmed">21372115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bsteh G., Hegen H., Ladst&#xe4;tter F., Berek K., Amprosi M., Wurth S., Auer M., Di Pauli F., Deisenhammer F., Reindl M., et al. Change of olfactory function as a marker of inflammatory activity and disability progression in MS. Mult. Scler. 2019;25:267&#x2013;274. doi: 10.1177/1352458517745724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458517745724</ArticleId><ArticleId IdType="pubmed">29185867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bsteh G., Berek K., Hegen H., Teuchner B., Auer M., Wurth S., Di Pauli F., Deisenhammer F., Berger T. Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration. Mult. Scler. 2020;26:57&#x2013;68. doi: 10.1177/1352458518814113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458518814113</ArticleId><ArticleId IdType="pubmed">30465490</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry J.D., Olschowka J.A., O&#x2019;Banion M.K. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J. Neuroinflamm. 2014;11:98. doi: 10.1186/1742-2094-11-98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-98</ArticleId><ArticleId IdType="pmc">PMC4060849</ArticleId><ArticleId IdType="pubmed">24889886</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelic M., Pontarelli F., Woodworth L., Zhu C., Mahan A., Ren Y., LaMorte M., Gruber R., Keane A., Loring P., et al. RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis. Cell Rep. 2021;35:109112. doi: 10.1016/j.celrep.2021.109112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109112</ArticleId><ArticleId IdType="pmc">PMC8917516</ArticleId><ArticleId IdType="pubmed">33979622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjelobaba I., Savic D., Lavrnja I. Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies. Curr. Pharm. Des. 2017;23:693&#x2013;730. doi: 10.2174/1381612822666161214153108.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612822666161214153108</ArticleId><ArticleId IdType="pubmed">27981909</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison A.G., Lin T., Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41:1100&#x2013;1115. doi: 10.1016/j.it.2020.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.10.004</ArticleId><ArticleId IdType="pmc">PMC7556779</ArticleId><ArticleId IdType="pubmed">33132005</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ascanio L., Pandolfini M., Cingolani C., Latini G., Gradoni P., Capalbo M., Frausini G., Maranzano M., Brenner M.J., Di Stadio A. Olfactory Dysfunction in COVID-19 Patients: Prevalence and Prognosis for Recovering Sense of Smell. Otolaryngol.&#x2013;Head Neck Surg. 2021;164:82&#x2013;86. doi: 10.1177/0194599820943530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820943530</ArticleId><ArticleId IdType="pubmed">32662745</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito F., Cirillo M., De Micco R., Caiazzo G., Siciliano M., Russo A.G., Monari C., Coppola N., Tedeschi G., Tessitore A. Olfactory loss and brain connectivity after COVID-19. Hum. Brain Mapp. 2022;43:1548&#x2013;1560. doi: 10.1002/hbm.25741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.25741</ArticleId><ArticleId IdType="pmc">PMC8886650</ArticleId><ArticleId IdType="pubmed">35083823</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., Rivera S.C., McMullan C., Chandan J.S., Haroon S., Price G., Davies E.H., Nirantharakumar K., et al. TLC Study Group. Symptoms, complications and management of long COVID: A review. J. R. Soc. Med. 2021;114:428&#x2013;442. doi: 10.1177/01410768211032850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., D&#x2019;Ascanio L., Vaira L.A., Cantone E., De Luca P., Cingolani C., Motta G., De Riu G., Vitelli F., Spriano G., et al. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial. Curr. Neuropharmacol. 2022;20:2001&#x2013;2012. doi: 10.2174/1570159X20666220420113513.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X20666220420113513</ArticleId><ArticleId IdType="pmc">PMC9886808</ArticleId><ArticleId IdType="pubmed">35450527</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ascanio L., Vitelli F., Cingolani C., Maranzano M., Brenner M.J., Di Stadio A. Randomized clinical trial &#x201c;olfactory dysfunction after COVID-19: Olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin&#x201d;: Preliminary results. Eur. Rev. Med. Pharmacol. Sci. 2021;25:4156&#x2013;4162. doi: 10.26355/eurrev_202106_26059.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202106_26059</ArticleId><ArticleId IdType="pubmed">34156697</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca P., Camaioni A., Marra P., Salzano G., Carriere G., Ricciardi L., Pucci R., Montemurro N., Brenner M.J., Di Stadio A. Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. Cells. 2022;11:2552. doi: 10.3390/cells11162552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11162552</ArticleId><ArticleId IdType="pmc">PMC9406356</ArticleId><ArticleId IdType="pubmed">36010630</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger J.R., Brandstadter R., Bar-Or A. COVID-19 and MS disease-modifying therapies. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e761. doi: 10.1212/NXI.0000000000000761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000761</ArticleId><ArticleId IdType="pmc">PMC7238896</ArticleId><ArticleId IdType="pubmed">32414755</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Byrne L., Webster K.E., MacKeith S., Philpott C., Hopkins C., Burton M.J. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst. Rev. 2022;7:CD013876. doi: 10.1002/14651858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858</ArticleId><ArticleId IdType="pmc">PMC8406942</ArticleId><ArticleId IdType="pubmed">34291813</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., Severini C., Colizza A., De Vincentiis M., La Mantia I. Investigational drugs for the treatment of olfactory dysfunction. Expert Opin. Investig. Drugs. 2022;31:945&#x2013;955. doi: 10.1080/13543784.2022.2113054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2022.2113054</ArticleId><ArticleId IdType="pubmed">35983993</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., D&#x2019;Ascanio L., La Mantia I., Ralli M., Brenner M.J. Parosmia after COVID-19: Olfactory training, neuroinflammation and distortions of smell. Eur. Rev. Med. Pharmacol. Sci. 2022;26:1&#x2013;3. doi: 10.26355/eurrev_202201_27739.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202201_27739</ArticleId><ArticleId IdType="pubmed">35049034</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishanth K., Tariq E., Nzvere F.P., Miqdad M., Cancarevic I. Role of Smoking in the Pathogenesis of Multiple Sclerosis: A Review Article. Cureus. 2020;12:e9564. doi: 10.7759/cureus.9564.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.9564</ArticleId><ArticleId IdType="pmc">PMC7473606</ArticleId><ArticleId IdType="pubmed">32905534</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Vargas A., C&#xe1;rcamo C., Henr&#xed;quez-Ch R., Zamorano F., Ciampi E., Uribe-San-Martin R., V&#xe1;squez M., Aboitiz F., Billeke P. Frontoparietal connectivity correlates with working memory performance in multiple sclerosis. Sci. Rep. 2020;10:9310. doi: 10.1038/s41598-020-66279-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-66279-0</ArticleId><ArticleId IdType="pmc">PMC7283327</ArticleId><ArticleId IdType="pubmed">32518271</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., Brenner M.J., De Luca P., Albanese M., D&#x2019;Ascanio L., Ralli M., Roccamatisi D., Cingolani C., Vitelli F., Camaioni A., et al. Olfactory Dysfunction, Headache, and Mental Clouding in Adults with Long-COVID-19: What Is the Link between Cognition and Olfaction? A Cross-Sectional Study. Brain Sci. 2022;12:154. doi: 10.3390/brainsci12020154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12020154</ArticleId><ArticleId IdType="pmc">PMC8870047</ArticleId><ArticleId IdType="pubmed">35203918</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., D&#x2019;Ascanio L., De Luca P., Roccamatisi D., La Mantia I., Brenner M.J. Hyperosmia after COVID-19: Hedonic perception or hypersensitivity? Eur. Rev. Med. Pharmacol. Sci. 2022;26:2196&#x2013;2200. doi: 10.26355/eurrev_202203_28368.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202203_28368</ArticleId><ArticleId IdType="pubmed">35363370</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Sabato D.J., Quan N., Godbout J.P. Neuroinflammation: The devil is in the details. J. Neurochem. 2016;139:136&#x2013;153. doi: 10.1111/jnc.13607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13607</ArticleId><ArticleId IdType="pmc">PMC5025335</ArticleId><ArticleId IdType="pubmed">26990767</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., Bernitsas E., Ralli M., Severini C., Brenner M.J., Angelini C. OAS1 gene, Spike protein variants and persistent COVID-19-related anosmia: May the olfactory disfunction be a harbinger of future neurodegenerative disease? Eur. Rev. Med. Pharmacol. Sci. 2022;26:347&#x2013;349. doi: 10.26355/eurrev_202201_27858.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202201_27858</ArticleId><ArticleId IdType="pubmed">35113409</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabot S., Yong V.W. Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: Relevance to MS. Neurology. 2000;55:1497&#x2013;1505. doi: 10.1212/WNL.55.10.1497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.10.1497</ArticleId><ArticleId IdType="pubmed">11094104</ArticleId></ArticleIdList></Reference><Reference><Citation>Mud&#xf2; G., Frinchi M., Nuzzo D., Scaduto P., Plescia F., Massenti M.F., Di Carlo M., Cannizzaro C., Cassata G., Cicero L., et al. Anti-inflammatory and cognitive effects of interferon-&#x3b2;1a (IFN&#x3b2;1a) in a rat model of Alzheimer&#x2019;s disease. J. Neuroinflammation. 2019;16:44. doi: 10.1186/s12974-019-1417-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1417-4</ArticleId><ArticleId IdType="pmc">PMC6380058</ArticleId><ArticleId IdType="pubmed">30777084</ArticleId></ArticleIdList></Reference><Reference><Citation>Begum-Haque S., Christy M., Wang Y., Kasper E., Ochoa-Reparaz J., Smith J.Y., Haque A., Kasper L.H. Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and ROR&#x3b3;t responses and by increasing IL-10 production in experimental allergic encephalomyelitis. J. Neuroimmunol. 2013;254:117&#x2013;124. doi: 10.1016/j.jneuroim.2012.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2012.10.003</ArticleId><ArticleId IdType="pubmed">23141166</ArticleId></ArticleIdList></Reference><Reference><Citation>Starossom S.C., Veremeyko T., Dukhinova M., Yung A.W., Ponomarev E.D. Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: Possible role of copaxone in targeting platelets during autoimmune neuroinflammation. PLoS ONE. 2014;9:e96256. doi: 10.1371/journal.pone.0096256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096256</ArticleId><ArticleId IdType="pmc">PMC4008572</ArticleId><ArticleId IdType="pubmed">24788965</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca P., Scarpa A., Ralli M., Tassone D., Simone M., De Campora L., Cassandro C., Di Stadio A. Auditory Disturbances and SARS-CoV-2 Infection: Brain Inflammation or Cochlear Affection? Systematic Review and Discussion of Potential Pathogenesis. Front. Neurol. 2021;12:707207. doi: 10.3389/fneur.2021.707207.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.707207</ArticleId><ArticleId IdType="pmc">PMC8373381</ArticleId><ArticleId IdType="pubmed">34421805</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai R.A., Davies A.L., Del Rossi N., Tachrount M., Dyson A., Gustavson B., Kaynezhad P., Mackenzie L., van der Putten M.A., McElroy D., et al. Nimodipine Reduces Dysfunction and Demyelination in Models of Multiple Sclerosis. Ann. Neurol. 2020;88:123&#x2013;136. doi: 10.1002/ana.25749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25749</ArticleId><ArticleId IdType="pmc">PMC7737229</ArticleId><ArticleId IdType="pubmed">32293054</ArticleId></ArticleIdList></Reference><Reference><Citation>Orefice N.S., Alhouayek M., Carotenuto A., Montella S., Barbato F., Comelli A., Calignano A., Muccioli G.G., Orefice G. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-&#x3b2;1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2016;13:428&#x2013;438. doi: 10.1007/s13311-016-0420-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0420-z</ArticleId><ArticleId IdType="pmc">PMC4824021</ArticleId><ArticleId IdType="pubmed">26857391</ArticleId></ArticleIdList></Reference><Reference><Citation>Nau R., Ribes S., Djukic M., Eiffert H. Strategies to increase the activity of microglia as efficient protectors of the brain against infections. Front. Cell. Neurosci. 2014;8:138. doi: 10.3389/fncel.2014.00138.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00138</ArticleId><ArticleId IdType="pmc">PMC4033068</ArticleId><ArticleId IdType="pubmed">24904283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S., Liu H., Chen Y., Qiu F., Liang C.L., Zhang Q., Huang H., Wang S., Zhang Z.D., Lu W., et al. A Novel Immunosuppressant, Luteolin, Modulates Alloimmunity and Suppresses Murine Allograft Rejection. J. Immunol. 2019;203:3436&#x2013;3446. doi: 10.4049/jimmunol.1900612.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1900612</ArticleId><ArticleId IdType="pubmed">31732527</ArticleId></ArticleIdList></Reference><Reference><Citation>Noce A., Albanese M., Marrone G., Di Lauro M., Zaitseva A.P., Palazzetti D., Guerriero C., Paolino A., Pizzenti G., Di Daniele F., et al. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in CO VID-19 patients. Pharmaceuticals. 2021;14:336. doi: 10.3390/ph14040336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14040336</ArticleId><ArticleId IdType="pmc">PMC8067485</ArticleId><ArticleId IdType="pubmed">33917573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>